Long-Term Safety Monitoring

Uses

Evidence quality

Highlighted claims

• The rare case strengthens the rationale for long-term monitoring after gene therapy. — A rare case of gene therapy-linked cancer
• Long-term surveillance remains necessary even for vector systems designed to avoid genome integration. — A rare case of gene therapy-linked cancer
• Short-term safety data cannot rule out late-emerging cancer risks linked to genomic integration. — A rare case of gene therapy-linked cancer
• The safety implication is limited by the fact that the case is rare among thousands of treated patients. — A rare case of gene therapy-linked cancer